CN102906265B - 脂质结合核酸 - Google Patents

脂质结合核酸 Download PDF

Info

Publication number
CN102906265B
CN102906265B CN201180024560.5A CN201180024560A CN102906265B CN 102906265 B CN102906265 B CN 102906265B CN 201180024560 A CN201180024560 A CN 201180024560A CN 102906265 B CN102906265 B CN 102906265B
Authority
CN
China
Prior art keywords
nucleic acid
acid molecules
binding
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180024560.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102906265A (zh
Inventor
W·普尔施克
S·克鲁斯曼
K·布驰尼尔
F·施沃布尔
K·赫利格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Publication of CN102906265A publication Critical patent/CN102906265A/zh
Application granted granted Critical
Publication of CN102906265B publication Critical patent/CN102906265B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
CN201180024560.5A 2010-04-21 2011-04-21 脂质结合核酸 Expired - Fee Related CN102906265B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10004253 2010-04-21
EP10004253.0 2010-04-21
EP11000117.9 2011-01-10
EP11000117 2011-01-10
PCT/EP2011/002068 WO2011131371A1 (en) 2010-04-21 2011-04-21 Lipid binding nucleic acids

Publications (2)

Publication Number Publication Date
CN102906265A CN102906265A (zh) 2013-01-30
CN102906265B true CN102906265B (zh) 2016-08-24

Family

ID=44201395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180024560.5A Expired - Fee Related CN102906265B (zh) 2010-04-21 2011-04-21 脂质结合核酸

Country Status (5)

Country Link
US (1) US8871920B2 (enExample)
EP (1) EP2561079A1 (enExample)
JP (1) JP5941904B2 (enExample)
CN (1) CN102906265B (enExample)
WO (1) WO2011131371A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140026357A (ko) * 2011-01-10 2014-03-05 녹손 파르마 아게 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법
BR112014016877B1 (pt) 2012-01-10 2022-03-15 Aptarion Biotech Ag Molécula de l-ácido nucleico capaz de se ligar a c5a humana, seus usos, bem como composição farmacêutica, complexo, método para a seleção de um antagonista de uma atividade mediada por c5a e kit para a detecção de c5a
SG11201403769YA (en) 2012-01-10 2014-07-30 Noxxon Pharma Ag Nucleic acids specifically binding cgrp
WO2017143220A1 (en) * 2016-02-17 2017-08-24 Children's Medical Center Corporation Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
EP3264092A1 (en) 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
EP3793427A1 (en) 2018-05-17 2021-03-24 The Procter & Gamble Company Systems and methods for hair coverage analysis
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
EP3814504A1 (en) 2018-06-29 2021-05-05 The Procter & Gamble Company Aptamers for personal care applications
US20200000697A1 (en) * 2018-06-29 2020-01-02 The Procter & Gamble Company Aptamers for hair care applications
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
US11806419B2 (en) 2019-04-16 2023-11-07 The Procter & Gamble Company Aptamers for odor control applications
CA3139314A1 (en) * 2019-07-17 2021-01-21 Noxopharm Limited Immuno-oncology therapy using isoflavone compounds
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225063B1 (en) * 1998-05-22 2001-05-01 University Technology Corporation RNA channels in biological membranes
WO2008124654A1 (en) * 2007-04-06 2008-10-16 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ES2346640T4 (es) 2001-10-26 2011-04-26 Noxxon Pharma Ag Ácido l-nucleico modificado.
EP2138575B8 (en) 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
WO2006052790A2 (en) 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
CA2607185A1 (en) 2005-05-04 2006-11-09 Noxxon Pharma Ag Intracellular active agents
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
EP2407558A1 (en) 2006-10-31 2012-01-18 Noxxon Pharma AG Methods for the detection of a single- or double-stranded nucleic acid molecule

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225063B1 (en) * 1998-05-22 2001-05-01 University Technology Corporation RNA channels in biological membranes
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
WO2008124654A1 (en) * 2007-04-06 2008-10-16 Lpath, Inc. Methods for decreasing immune response and treating immune conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Binding and disruption of phospholipid bilayers by supramolecular RNA complexes;Alexandre Vlassov et al;《PNAS》;20010703;第98卷(第14期);摘要、图2、4 *
Development of a Sphingosylphosphorylcholine Detection System Using RNA Aptamers;Katsunori Horii et al;《Molecules》;20100820;第15卷;摘要、图4、表1 *
Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer;Steffen Helmling et al;《PNAS》;20040907;第101卷(第36期);13178页左栏 *
Spiegelmers Biostable Aptamers;Dirk Eulberg andSven Klussmann;《ChemBioChem》;20031006;第4卷;979-983 *
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages;Barbara Visentin et al;《CANCER CELL》;20060223;第9卷;225-238 *

Also Published As

Publication number Publication date
US20130165501A1 (en) 2013-06-27
EP2561079A1 (en) 2013-02-27
AU2011244628A1 (en) 2012-11-08
AU2011244628B2 (en) 2016-01-07
WO2011131371A1 (en) 2011-10-27
AU2011244628A2 (en) 2012-11-08
CN102906265A (zh) 2013-01-30
JP2013524792A (ja) 2013-06-20
US8871920B2 (en) 2014-10-28
JP5941904B2 (ja) 2016-06-29

Similar Documents

Publication Publication Date Title
CN102906265B (zh) 脂质结合核酸
JP5798549B2 (ja) ヘプシジン結合核酸
JP6587934B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
US9486538B2 (en) Lipids, lipid complexes and use thereof
CN109106722B (zh) 适体在自体免疫疾病的疗法和/或诊断中的用途
JP6437467B2 (ja) 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法
JP6949818B2 (ja) 運動精子ドメイン含有タンパク質２及びがん
JP6949916B2 (ja) 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
CN115175685A (zh) 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
JP2025504931A (ja) 関節機能を改善する遺伝子編集
AU2011244628B9 (en) Lipid binding nucleic acids
KR102132222B1 (ko) 항암제 내성 진단 마커로서의 miR-143-3p 및 miR-373-5p, 및 이의 이용
WO2020163974A1 (zh) 针对骨硬化蛋白的适体的诊断用途
JP2016518812A (ja) 線維症治療において有用な分子標的及び前記標的のインヒビター
AU2015268717A1 (en) Lipid binding nucleic acids
KR20160138215A (ko) 오토탁신에 결합하여 오토탁신의 생리 활성을 저해하는 압타머 및 그의 이용
WO2025179844A1 (zh) 靶向结缔组织生长因子蛋白的适配体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160824

Termination date: 20170421